Synthesis, Pharmacological Evaluation and Docking Study of a New Modulator of Microtubule Polymerization
作者:Teiliane R. Carneiro、Daniel N. do Amaral、Harold H. Fokoue、Carlos M.R. Sant`Anna、Maria L.G. Porras、Augusto C.A. Oliveira、Bruno C. Cavalcanti、Claudia Pessoa、Eliezer J. Barreiro、Lidia M. Lima
DOI:10.2174/1570180814666171012162557
日期:2018.5.30
this paper was to conduct the synthesis to determine cytotoxic activity and to carry out docking studies on new LASSBio-1586 isosteres. LASSBio-1586 is a new combretastatin A4 (CA4) analogue previously identified as a simple antitumor drug candidate, able to inhibit microtubule polymerization with broad in vitro and in vivo cytotoxic activity. Methods: The new isosteres (7b-7h, 8a and 9a) were evaluated
目的:本文的主要目的是进行合成以确定细胞毒活性,并进行对新的LASSBio-1586等位基因的对接研究。LASSBio-1586是一种新的康普他汀A4(CA4)类似物,以前被认为是一种简单的抗肿瘤药物候选物,能够抑制微管聚合,具有广泛的体外和体内细胞毒活性。 方法:使用MTT的细胞毒性试验评估新的等位基因(7b-7h,8a和9a)对HL-60,OVCAR-8,HCT8和LUCENA肿瘤细胞系的影响。微管蛋白聚合测定是使用来自cytoskeleton?的微管蛋白聚合测定试剂盒和CEREP,使用10 µM的单一浓度进行的。通过盲分子对接研究建立了β-微管蛋白秋水仙碱结合位点的结合模式。 结果:尽管LASSBio-1920(7h)对MDR肿瘤细胞系LUCENA(IC50 = 80 µM)无活性,但其IC50值范围为0.75 nM至11.5 nM,被认为是最有效的细胞毒性化合物。与CA4和LASS